Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Massimo Loda, M.D.

TitleProfessor of Pathology
InstitutionDana-Farber Cancer Institute
DepartmentPathology
AddressDana Farber Cancer Institute
D-740
44 Binney St
Boston MA 02115
Phone617/632-4001
Fax617/632-4005

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA. Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
  2. Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2354-63.
    View in: PubMed
  3. Kaelin W, Livingston D, Loda M, Vousden K, Mihich E. Twenty-fifth Annual Pezcoller Symposium: Metabolism and Tumorigenesis. Cancer Res. 2013 Oct 15; 73(20):6124-7.
    View in: PubMed
  4. Benassi B, Marani M, Loda M, Blandino G. USP2a alters chemotherapeutic response by modulating redox. Cell Death Dis. 2013; 4:e812.
    View in: PubMed
  5. Chavarro JE, Kenfield SA, Stampfer MJ, Loda M, Campos H, Sesso HD, Ma J. Blood levels of saturated and monounsaturated Fatty acids as markers of de novo lipogenesis and risk of prostate cancer. Am J Epidemiol. 2013 Oct 15; 178(8):1246-55.
    View in: PubMed
  6. Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E. Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):1984-93.
    View in: PubMed
  7. Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
    View in: PubMed
  8. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013 Jun 2; 45(7):747-55.
    View in: PubMed
  9. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013 May 1; 73(9):2718-36.
    View in: PubMed
  10. Zadra G, Photopoulos C, Loda M. The fat side of prostate cancer. Biochim Biophys Acta. 2013 Oct; 1831(10):1518-32.
    View in: PubMed
  11. Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC, Orkin SH, Li Z. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 2013 Mar 15; 27(6):683-98.
    View in: PubMed
  12. Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013 Mar 1; 123(3):1109-22.
    View in: PubMed
  13. Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U. Metformin--an Adjunct Antineoplastic Therapy--Divergently Modulates Tumor Metabolism and Proliferation, Interfering with Early Response Prediction by 18F-FDG PET Imaging. J Nucl Med. 2013 Feb; 54(2):252-8.
    View in: PubMed
  14. Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol. 2013; 2013:823849.
    View in: PubMed
  15. Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013 Jan; 3(1):44-51.
    View in: PubMed
  16. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012 Dec 14; 338(6113):1465-9.
    View in: PubMed
  17. Kim J, Keay SK, You S, Loda M, Freeman MR. A Synthetic Form of Frizzled 8-Associated Antiproliferative Factor Enhances p53 Stability through USP2a and MDM2. PLoS One. 2012; 7(12):e50392.
    View in: PubMed
  18. Penney KL, Li H, Mucci LA, Loda M, Sesso HD, Stampfer MJ, Ma J. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013 May; 73(7):700-5.
    View in: PubMed
  19. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
  20. Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack EC, Lis R, Kantoff PW, Loda M, Sartor O, Egawa S, Tewari AK, Hahn WC, Freedman ML. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7.
    View in: PubMed
  21. Liu Z, Zanata SM, Kim J, Peterson MA, Di Vizio D, Chirieac LR, Pyne S, Agostini M, Freeman MR, Loda M. The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation. Oncogene. 2013 Mar 28; 32(13):1660-9.
    View in: PubMed
  22. Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881.
    View in: PubMed
  23. Wu X, Zhou J, Rogers AM, Jänne PA, Benedettini E, Loda M, Hodi FS. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 2012 Apr; 22(2):123-32.
    View in: PubMed
  24. Fiore C, Bailey D, Conlon N, Wu X, Martin N, Fiorentino M, Finn S, Fall K, Andersson SO, Andren O, Loda M, Flavin R. Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry. J Clin Pathol. 2012 Jun; 65(6):496-502.
    View in: PubMed
  25. Kim J, Kim WJ, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 2012 Mar 15; 11(6):1123-30.
    View in: PubMed
  26. Benassi B, Flavin R, Marchionni L, Zanata S, Pan Y, Chowdhury D, Marani M, Strano S, Muti P, Blandino G, Loda M. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. 2012 Mar; 2(3):236-47.
    View in: PubMed
  27. Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis. 2012 Feb; 33(2):404-12.
    View in: PubMed
  28. Martin NE, Mucci LA, Loda M, Depinho RA. Prognostic determinants in prostate cancer. Cancer J. 2011 Nov-Dec; 17(6):429-37.
    View in: PubMed
  29. Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, Draetta GF, Fletcher CD, Loda M. Investigative pathology: leading the post-genomic revolution. Lab Invest. 2012 Jan; 92(1):4-8.
    View in: PubMed
  30. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
    View in: PubMed
  31. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011 Jun; 35(6):816-26.
    View in: PubMed
  32. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
  33. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA, Giovannucci E. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
  34. Flavin RJ, Cook J, Fiorentino M, Bailey D, Brown M, Loda MF. ß-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. Am J Clin Pathol. 2011 May; 135(5):776-82.
    View in: PubMed
  35. Nardella C, Lunardi A, Fedele G, Clohessy JG, Alimonti A, Kozma SC, Thomas G, Loda M, Pandolfi PP. Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. Cancer Res. 2011 May 15; 71(10):3669-75.
    View in: PubMed
  36. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, Mermel CH, Loda M, Ait-Si-Ali S, Garraway LA, Young RA, Zon LI. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011 Mar 24; 471(7339):513-7.
    View in: PubMed
  37. Lee SH, Jia S, Zhu Y, Utermark T, Signoretti S, Loda M, Schaffhausen B, Roberts TM. Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma. J Virol. 2011 Jun; 85(11):5581-92.
    View in: PubMed
  38. Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O. RET protein expression in papillary renal cell carcinoma. Urol Oncol. 2012 Nov; 30(6):900-5.
    View in: PubMed
  39. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011 Feb 10; 470(7333):269-73.
    View in: PubMed
  40. Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011 Jan; 223(2):283-94.
    View in: PubMed
  41. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov; 6(11):e1001204.
    View in: PubMed
  42. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer. 2011 Mar 15; 117(6):1172-82.
    View in: PubMed
  43. Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer. 2010 Sep 28; 103(7):1025-33.
    View in: PubMed
  44. Kenney PA, Wszolek MF, Rieger-Christ KM, Neto BS, Gould JJ, Harty NJ, Mosquera JM, Zeheb R, Loda M, Darling DS, Libertino JA, Summerhayes IC. Novel ZEB1 expression in bladder tumorigenesis. BJU Int. 2011 Feb; 107(4):656-63.
    View in: PubMed
  45. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 1; 28(25):3958-64.
    View in: PubMed
  46. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev. 2010 Aug; 19(8):2088-96.
    View in: PubMed
  47. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
    View in: PubMed
  48. Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A. 2010 Jun 15; 107(24):11002-7.
    View in: PubMed
  49. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, Ligon AH, Pan BS, Richon V, Minna JD, Gazdar AF, Draetta G, Bosari S, Chirieac LR, Lutterbach B, Loda M. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010 Jul; 177(1):415-23.
    View in: PubMed
  50. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer. 2010 May 11; 102(10):1495-502.
    View in: PubMed
  51. Zadra G, Priolo C, Patnaik A, Loda M. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res. 2010 Jul 1; 16(13):3322-8.
    View in: PubMed
  52. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010 May 4; 107(18):8352-6.
    View in: PubMed
  53. Loda M, Kaelin WG. Prostate cancer: beta control your hormones. Cancer Cell. 2010 Apr 13; 17(4):311-2.
    View in: PubMed
  54. Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
  55. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010; 3(117):ra29.
    View in: PubMed
  56. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010 Apr; 6(4):551-62.
    View in: PubMed
  57. Priolo C, Agostini M, Vena N, Ligon AH, Fiorentino M, Shin E, Farsetti A, Pontecorvi A, Sicinska E, Loda M. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol. 2010 Apr; 176(4):1901-13.
    View in: PubMed
  58. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
  59. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010 Mar; 16(3):286-94.
    View in: PubMed
  60. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A. 2010 Feb 23; 107(8):3698-703.
    View in: PubMed
  61. Fiorentino M, Capizzi E, Loda M. Blood and tissue biomarkers in prostate cancer: state of the art. Urol Clin North Am. 2010 Feb; 37(1):131-41, Table of Contents.
    View in: PubMed
  62. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 2009 Nov 1; 69(21):8341-8.
    View in: PubMed
  63. Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009 Oct 1; 69(19):7803-10.
    View in: PubMed
  64. Wadlow RC, Wittner BS, Finley SA, Bergquist H, Upadhyay R, Finn S, Loda M, Mahmood U, Ramaswamy S. Systems-level modeling of cancer-fibroblast interaction. PLoS One. 2009; 4(9):e6888.
    View in: PubMed
  65. Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, Nosho K, Shima K, Giovannucci EL, Loda M, Fuchs CS. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5931-6.
    View in: PubMed
  66. Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal. 2009; 2(84):ra44.
    View in: PubMed
  67. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009 Aug; 36(4):290-301.
    View in: PubMed
  68. Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis WD, Loda M, Chirieac LR. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009 Aug; 13(8B):1977-86.
    View in: PubMed
  69. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009 Jul 23; 138(2):245-56.
    View in: PubMed
  70. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin P, Fletcher CD. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol. 2009 Jul; 218(3):292-300.
    View in: PubMed
  71. Sabbisetti V, Di Napoli A, Seeley A, Amato AM, O'Regan E, Ghebremichael M, Loda M, Signoretti S. p63 promotes cell survival through fatty acid synthase. PLoS One. 2009; 4(6):e5877.
    View in: PubMed
  72. Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest. 2009 Aug; 89(8):857-66.
    View in: PubMed
  73. Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 2009 Jun 1; 15(11):3680-9.
    View in: PubMed
  74. Nguyen PL, Lin DI, Lei J, Fiorentino M, Mueller E, Weinstein MH, Pagano M, Loda M. The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy. Urol Oncol. 2011 May-Jun; 29(3):302-8.
    View in: PubMed
  75. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20; 27(21):3459-64.
    View in: PubMed
  76. Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, Laios A, O'Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O'Leary JJ. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer. 2009 May; 19(4):641-7.
    View in: PubMed
  77. Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X, Comb MJ. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009 May 1; 15(9):3023-8.
    View in: PubMed
  78. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M, Farsetti A. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest. 2009 May; 119(5):1093-108.
    View in: PubMed
  79. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 1; 101(7):519-32.
    View in: PubMed
  80. Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009 Mar 15; 15(6):2116-22.
    View in: PubMed
  81. Priolo C, Oh WK, Loda M. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. IDrugs. 2009 Mar; 12(3):165-8.
    View in: PubMed
  82. Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal. 2009; 2(55):ra2.
    View in: PubMed
  83. Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009 Jan; 27(1):77-83.
    View in: PubMed
  84. Jeong JH, Wang Z, Guimaraes AS, Ouyang X, Figueiredo JL, Ding Z, Jiang S, Guney I, Kang GH, Shin E, Hahn WC, Loda MF, Abate-Shen C, Weissleder R, Chin L. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One. 2008; 3(12):e3949.
    View in: PubMed
  85. Carvalho MA, Zecchin KG, Seguin F, Bastos DC, Agostini M, Rangel AL, Veiga SS, Raposo HF, Oliveira HC, Loda M, Coletta RD, Graner E. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer. 2008 Dec 1; 123(11):2557-65.
    View in: PubMed
  86. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008 Dec 10; 26(35):5713-20.
    View in: PubMed
  87. Mandeville JA, Silva Neto B, Vanni AJ, Smith GL, Rieger-Christ KM, Zeheb R, Loda M, Libertino JA, Summerhayes IC. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells. BJU Int. 2008 Dec; 102(11):1707-14.
    View in: PubMed
  88. Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer. 2008 Oct 15; 113(8):2129-38.
    View in: PubMed
  89. Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88(12):1340-8.
    View in: PubMed
  90. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009 Jan; 58(1):90-6.
    View in: PubMed
  91. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455(7212):547-51.
    View in: PubMed
  92. Levenson RM, Fornari A, Loda M. Multispectral imaging and pathology: seeing and doing more. Expert Opin Med Diagn. 2008 Sep; 2(9):1067-81.
    View in: PubMed
  93. Ince TA, Ward JM, Valli VE, Sgroi D, Nikitin AY, Loda M, Griffey SM, Crum CP, Crawford JM, Bronson RT, Cardiff RD. Do-it-yourself (DIY) pathology. Nat Biotechnol. 2008 Sep; 26(9):978-9; discussion 979.
    View in: PubMed
  94. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12; 14(2):146-55.
    View in: PubMed
  95. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 Aug 7; 454(7205):776-9.
    View in: PubMed
  96. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008 Jun 1; 14(11):3380-5.
    View in: PubMed
  97. Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T, Demichelis F, Solomon KR, Loda M, Rubin MA, Lisanti MP, Freeman MR. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle. 2008 Jul 15; 7(14):2257-67.
    View in: PubMed
  98. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O' Leary J. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008; 7:35.
    View in: PubMed
  99. Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ. Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 2008 Jun; 21(6):676-84.
    View in: PubMed
  100. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008 Mar; 15(1):191-205.
    View in: PubMed
  101. Swain RS, Tihan T, Horvai AE, Di Vizio D, Loda M, Burger PC, Scheithauer BW, Kim GE. Inflammatory myofibroblastic tumor of the central nervous system and its relationship to inflammatory pseudotumor. Hum Pathol. 2008 Mar; 39(3):410-9.
    View in: PubMed
  102. Febbo PG, Mulligan MG, Slonina DA, Stegmaier K, Di Vizio D, Martinez PR, Loda M, Taylor SC. Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis. BMC Genomics. 2007; 8:461.
    View in: PubMed
  103. Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, Ogino S. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2008 Feb; 21(2):150-8.
    View in: PubMed
  104. Hittelman A, Sridharan S, Roy R, Fridlyand J, Loda M, Collins C, Paris PL. Evaluation of whole genome amplification protocols for array and oligonucleotide CGH. Diagn Mol Pathol. 2007 Dec; 16(4):198-206.
    View in: PubMed
  105. Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, Sellers WR. Identification of prostate cancer modifier pathways using parental strain expression mapping. Proc Natl Acad Sci U S A. 2007 Nov 6; 104(45):17771-6.
    View in: PubMed
  106. Silva Neto B, Smith GL, Mandeville JA, Vanni AJ, Wotkowicz C, Rieger-Christ KM, Baumgart E, Jacobs MA, Cohen MS, Zeheb R, Loda M, Libertino JA, Summerhayes IC. Prognostic significance of altered p120 ctn expression in bladder cancer. BJU Int. 2008 Mar; 101(6):746-52.
    View in: PubMed
  107. Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007 Sep; 9(4):441-51.
    View in: PubMed
  108. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007 Jul; 9(3):305-14.
    View in: PubMed
  109. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 2007 Jun; 11(6):555-69.
    View in: PubMed
  110. Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR, Lisanti MP. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther. 2007 Aug; 6(8):1263-8.
    View in: PubMed
  111. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37.
    View in: PubMed
  112. Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M, Libertino JA, Summerhayes IC. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res. 2007 Mar 15; 13(6):1685-94.
    View in: PubMed
  113. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol. 2007 Jun; 38(6):842-9.
    View in: PubMed
  114. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
    View in: PubMed
  115. Byers RJ, Di Vizio D, O'connell F, Tholouli E, Levenson RM, Gossage K, Gossard K, Twomey D, Yang Y, Benedettini E, Rose J, Ligon KL, Finn SP, Golub TR, Loda M. Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn. 2007 Feb; 9(1):20-9.
    View in: PubMed
  116. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol. 2007 Apr; 38(4):614-20.
    View in: PubMed
  117. Nieto M, Finn S, Loda M, Hahn WC. Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol. 2007; 39(9):1562-8.
    View in: PubMed
  118. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol. 2007 Apr; 38(4):585-92.
    View in: PubMed
  119. Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol. 2007 Jan; 20(1):15-22.
    View in: PubMed
  120. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006 Nov; 8(5):582-8.
    View in: PubMed
  121. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Farree X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Hoque A, Lucia MS. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol. 2006 Oct; 30(10):1281-91.
    View in: PubMed
  122. Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol. 2006 Oct; 210(2):147-54.
    View in: PubMed
  123. Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol. 2006 Sep; 30(9):1175-83.
    View in: PubMed
  124. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 2006 Sep 1; 66(17):8625-32.
    View in: PubMed
  125. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 2006 Aug 1; 66(15):7668-77.
    View in: PubMed
  126. Tholouli E, Hoyland JA, Di Vizio D, O'Connell F, Macdermott SA, Twomey D, Levenson R, Yin JA, Golub TR, Loda M, Byers R. Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies. Biochem Biophys Res Commun. 2006 Sep 22; 348(2):628-36.
    View in: PubMed
  127. Rossi S, Ou W, Tang D, Bhattacharya N, Dei Tos AP, Fletcher JA, Loda M. Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol. 2006 Jul; 209(3):369-75.
    View in: PubMed
  128. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia. 2006 Jun; 8(6):458-64.
    View in: PubMed
  129. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 Jun 1; 66(11):5723-8.
    View in: PubMed
  130. Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006 Jun; 5(1):61-6.
    View in: PubMed
  131. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol. 2006 Aug; 19(8):1083-90.
    View in: PubMed
  132. Signoretti S, Loda M. Prostate stem cells: from development to cancer. Semin Cancer Biol. 2007 Jun; 17(3):219-24.
    View in: PubMed
  133. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006 May; 8(2):209-17.
    View in: PubMed
  134. Nucera C, Vaccaro M, Moleti M, Priolo C, Tortorella G, Angioni A, Ientile R, Violi MA, Loda M, Trimarchi F, Vermiglio F. antiphospholipid antibodies syndrome associated with hyperhomocysteinemia related to MTHFR Gene C677T and A1298C heterozygous mutations in a young man with idiopathic hypoparathyroidism (DiGeorge syndrome). J Clin Endocrinol Metab. 2006 Jun; 91(6):2021-6.
    View in: PubMed
  135. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, Zupi G, Biroccio A. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell. 2006 Feb 17; 21(4):509-19.
    View in: PubMed
  136. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res. 2006 Feb; 4(2):79-92.
    View in: PubMed
  137. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate. 2006 Feb 1; 66(2):135-45.
    View in: PubMed
  138. Signoretti S, Loda M. Defining cell lineages in the prostate epithelium. Cell Cycle. 2006 Jan; 5(2):138-41.
    View in: PubMed
  139. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006 Jul; 55(7):1000-6.
    View in: PubMed
  140. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub T, George D. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006 Jan 1; 12(1):152-8.
    View in: PubMed
  141. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006 Jan; 19(1):59-68.
    View in: PubMed
  142. Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson RT, Noda M, Loda M, Hunt JL, Ewen ME. Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nat Genet. 2006 Jan; 38(1):118-23.
    View in: PubMed
  143. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005 Dec 20; 102(51):18443-8.
    View in: PubMed
  144. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6.
    View in: PubMed
  145. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005 Aug; 7(3):413-21.
    View in: PubMed
  146. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A. 2005 Aug 9; 102(32):11355-60.
    View in: PubMed
  147. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005 Jul 15; 11(14):5233-40.
    View in: PubMed
  148. Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2005 Jul 19; 102(29):10238-43.
    View in: PubMed
  149. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005 Jun 15; 65(12):5054-62.
    View in: PubMed
  150. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol. 2005 May; 173(5):1772-7.
    View in: PubMed
  151. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M, Lisanti MP. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem. 2005 Jul 1; 280(26):25134-45.
    View in: PubMed
  152. Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S, Brooks JD, Loda M, Reiter RE. Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res. 2005 Mar 15; 11(6):2237-43.
    View in: PubMed
  153. Lechpammer M, Xu X, Ellis FH, Bhattacharaya N, Shapiro GI, Loda M. Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice. Oncogene. 2005 Mar 3; 24(10):1683-8.
    View in: PubMed
  154. Han WK, Alinani A, Wu CL, Michaelson D, Loda M, McGovern FJ, Thadhani R, Bonventre JV. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol. 2005 Apr; 16(4):1126-34.
    View in: PubMed
  155. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75.
    View in: PubMed
  156. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol. 2004 Dec; 35(12):1462-8.
    View in: PubMed
  157. Takahashi C, Contreras B, Bronson RT, Loda M, Ewen ME. Genetic interaction between Rb and K-ras in the control of differentiation and tumor suppression. Mol Cell Biol. 2004 Dec; 24(23):10406-15.
    View in: PubMed
  158. Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, Corless CL. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004 Nov; 17(11):1392-9.
    View in: PubMed
  159. Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res. 2004 Sep; 2(9):489-94.
    View in: PubMed
  160. Korkmaz CG, Korkmaz KS, Manola J, Xi Z, Risberg B, Danielsen H, Kung J, Sellers WR, Loda M, Saatcioglu F. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J Urol. 2004 Sep; 172(3):1134-9.
    View in: PubMed
  161. Murphy M, Carlson JA, Keough MP, Claffey KP, Signoretti S, Loda M. Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27. J Cutan Pathol. 2004 Aug; 31(7):477-82.
    View in: PubMed
  162. Agostini M, Silva SD, Zecchin KG, Coletta RD, Jorge J, Loda M, Graner E. Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells. Oral Oncol. 2004 Aug; 40(7):728-35.
    View in: PubMed
  163. Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res. 2004 Jul 15; 10(14):4680-7.
    View in: PubMed
  164. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004 Jun; 10(6):594-601.
    View in: PubMed
  165. Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M, Saatcioglu F. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 2004 Apr 1; 64(7):2365-70.
    View in: PubMed
  166. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004 Mar; 5(3):253-61.
    View in: PubMed
  167. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 1; 10(3):828-39.
    View in: PubMed
  168. Pachori AS, Melo LG, Zhang L, Loda M, Pratt RE, Dzau VJ. Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem Biophys Res Commun. 2004 Jan 16; 313(3):528-33.
    View in: PubMed
  169. Ellis FH, Loda M. p27 and Barrett's esophagus: a review*. Dis Esophagus. 2004; 17(2):113-7.
    View in: PubMed
  170. Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem. 2004 Jan 1; 91(1):47-53.
    View in: PubMed
  171. Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004 Mar; 19(2):114-20.
    View in: PubMed
  172. Moreira Júnior G, Colleoni GW, Cangi MG, Murphy M, Sherburne B, Bordin JO, Loda M. Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol. 2003 Sep; 12(3):128-32.
    View in: PubMed
  173. Hinoi T, Loda M, Fearon ER. Silencing of CDX2 expression in colon cancer via a dominant repression pathway. J Biol Chem. 2003 Nov 7; 278(45):44608-16.
    View in: PubMed
  174. Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res. 2003 Aug 15; 63(16):4781-5.
    View in: PubMed
  175. Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003 Aug; 1(10):765-75.
    View in: PubMed
  176. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003 Aug; 1(10):707-15.
    View in: PubMed
  177. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A. 2003 Jun 24; 100(13):7841-6.
    View in: PubMed
  178. Kukoski R, Blonigen B, Macri E, Renshaw AA, Hoffman M, Loda M, Datta MW. p27 and cyclin E/D2 associations in testicular germ cell tumors: implications for tumorigenesis. Appl Immunohistochem Mol Morphol. 2003 Jun; 11(2):138-43.
    View in: PubMed
  179. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate. 2003 May 15; 55(3):206-18.
    View in: PubMed
  180. Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J. 2003 May-Jun; 9(3):208-12.
    View in: PubMed
  181. Fleming MD, Pinkus JL, Fournier MV, Alexander SW, Tam C, Loda M, Sallan SE, Nichols KE, Carpentieri DF, Pinkus GS, Rollins BJ. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood. 2003 Apr 1; 101(7):2473-5.
    View in: PubMed
  182. Barbareschi M, Murer B, Colby TV, Chilosi M, Macri E, Loda M, Doglioni C. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol. 2003 Feb; 27(2):141-9.
    View in: PubMed
  183. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat. 2003 Feb; 77(3):245-52.
    View in: PubMed
  184. Fujishita T, Loda M, Turner RE, Gentler M, Kashii T, Breathnach OS, Johnson BE. Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel. Oncology. 2003; 64(4):399-406.
    View in: PubMed
  185. Osipov V, Keating JT, Faul PN, Loda M, Datta MW. Expression of p27 and VHL in renal tumors. Appl Immunohistochem Mol Morphol. 2002 Dec; 10(4):344-50.
    View in: PubMed
  186. Lindeman N, Waltregny D, Signoretti S, Loda M. Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection. Diagn Mol Pathol. 2002 Dec; 11(4):187-92.
    View in: PubMed
  187. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002 Dec; 15(12):1302-8.
    View in: PubMed
  188. Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell. 2002 Nov; 2(5):349-50.
    View in: PubMed
  189. Rossi S, Loda M. The role of the ubiquitination-proteasome pathway in breast cancer: use of mouse models for analyzing ubiquitination processes. Breast Cancer Res. 2003; 5(1):16-22.
    View in: PubMed
  190. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature. 2002 Sep 12; 419(6903):162-7.
    View in: PubMed
  191. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002 Sep; 110(5):633-41.
    View in: PubMed
  192. Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 2002 Jul 15; 62(14):3925-8.
    View in: PubMed
  193. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem. 2002 Sep 27; 277(39):36689-96.
    View in: PubMed
  194. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002 Nov 15; 100(10):3776-81.
    View in: PubMed
  195. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, Kolodner RD, Fox E. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res. 2002 Jun 15; 62(12):3485-92.
    View in: PubMed
  196. Oh WK, Loda M, Kantoff PW, Janicek M. Progressive sclerosis of isolated foot metastasis of prostate cancer. J Urol. 2002 Mar; 167(3):1392.
    View in: PubMed
  197. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002 Mar; 1(2):203-9.
    View in: PubMed
  198. DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M, Brown M. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 2002 Jan 1; 62(1):89-98.
    View in: PubMed
  199. Bardeesy N, Morgan J, Sinha M, Signoretti S, Srivastava S, Loda M, Merlino G, DePinho RA. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol. 2002 Jan; 22(2):635-43.
    View in: PubMed
  200. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001 Dec 18; 98(26):15149-54.
    View in: PubMed
  201. Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, Loda M, Appelman HD, Cho KR, Fearon ER. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001 Dec; 159(6):2239-48.
    View in: PubMed
  202. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13790-5.
    View in: PubMed
  203. Ellis FH, Xu X, Kulke MH, LoCicero J, Loda M. Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice. J Thorac Cardiovasc Surg. 2001 Oct; 122(4):809-14.
    View in: PubMed
  204. DeSalle LM, Latres E, Lin D, Graner E, Montagnoli A, Baker RT, Pagano M, Loda M. The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein. Oncogene. 2001 Sep 6; 20(39):5538-42.
    View in: PubMed
  205. Sasaki H, Lo KM, Chen LB, Auclair D, Nakashima Y, Moriyama S, Fukai I, Tam C, Loda M, Fujii Y. Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res. 2001 Aug; 92(8):869-73.
    View in: PubMed
  206. Signoretti S, Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol. 2001 Jul; 159(1):13-6.
    View in: PubMed
  207. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol. 2001 May; 15(5):765-82.
    View in: PubMed
  208. Datta MW, Macri E, Signoretti S, Renshaw AA, Loda M. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. Mod Pathol. 2001 May; 14(5):437-42.
    View in: PubMed
  209. Kulke MH, Thakore KS, Thomas G, Wang H, Loda M, Eng C, Odze RD. Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer. 2001 Apr 15; 91(8):1451-7.
    View in: PubMed
  210. Fernández-Santos JM, Utrilla JC, Conde E, Hevia A, Loda M, Martín-Lacave I. Decrease in calcitonin and parathyroid hormone mRNA levels and hormone secretion under long-term hypervitaminosis D3 in rats. Histol Histopathol. 2001 Apr; 16(2):407-14.
    View in: PubMed
  211. Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M, Eng C. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer. 2001 Mar 23; 84(6):748-53.
    View in: PubMed
  212. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000 Dec 15; 275(50):39223-30.
    View in: PubMed
  213. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 6; 92(23):1918-25.
    View in: PubMed
  214. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000 Dec; 20(23):8969-82.
    View in: PubMed
  215. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000 Dec; 157(6):1769-75.
    View in: PubMed
  216. Fiorentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WF. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res. 2000 Oct; 6(10):3966-72.
    View in: PubMed
  217. Loda M. p27KIP1: androgen regulation and prognostic significance in prostate cancer. Adv Clin Path. 2000 Oct; 4(4):226-32.
    View in: PubMed
  218. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G, Ranashinge M, Cady B, Pagano M, Loda M. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000 Sep; 106(6):753-61.
    View in: PubMed
  219. Murphy M, Signoretti S, Kadin ME, Loda M. Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. J Cutan Pathol. 2000 May; 27(5):228-34.
    View in: PubMed
  220. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000 Mar 23; 404(6776):407-11.
    View in: PubMed
  221. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000 Mar 2; 19(10):1288-96.
    View in: PubMed
  222. Xu X, LoCicero J, Macri E, Loda M, Ellis FH. Barrett's esophagus and associated adenocarcinoma in a mouse surgical model. J Surg Res. 2000 Feb; 88(2):120-4.
    View in: PubMed
  223. Loda M, Xu X, Pession A, Vortmeyer A, Giangaspero F. Membranous expression of glucose transporter-1 protein (GLUT-1) in embryonal neoplasms of the central nervous system. Neuropathol Appl Neurobiol. 2000 Feb; 26(1):91-7.
    View in: PubMed
  224. Chiaur DS, Murthy S, Cenciarelli C, Parks W, Loda M, Inghirami G, Demetrick D, Pagano M. Five human genes encoding F-box proteins: chromosome mapping and analysis in human tumors. Cytogenet Cell Genet. 2000; 88(3-4):255-8.
    View in: PubMed
  225. Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer. 2000 Jan; 27(1):95-103.
    View in: PubMed
  226. Khettry U, Anand N, Gordon FD, Jenkins RL, Tahan SR, Loda M, Lewis WD. Recurrent hepatitis B, hepatitis C, and combined hepatitis B and C in liver allografts: a comparative pathological study. Hum Pathol. 2000 Jan; 31(1):101-8.
    View in: PubMed
  227. Signoretti S, Murphy M, Puddu P, DeCoteau JF, Faraggiana T, Kadin ME, Loda M. Clonality of cutaneous B-cell infiltrates determined by microdissection and immunoglobulin gene rearrangement. Diagn Mol Pathol. 1999 Dec; 8(4):176-82.
    View in: PubMed
  228. Walsh S, Murphy M, Silverman M, Odze R, Antonioli D, Goldman H, Loda M. p27 expression in inflammatory bowel disease-associated neoplasia. Further evidence of a unique molecular pathogenesis. Am J Pathol. 1999 Nov; 155(5):1511-8.
    View in: PubMed
  229. Murphy M, Signoretti S, Nasser I, Sherburne B, Loda M. Detection of concurrent/recurrent non-Hodgkin's lymphoma in effusions by PCR. Hum Pathol. 1999 Nov; 30(11):1361-6.
    View in: PubMed
  230. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999 Sep 1; 59(17):4291-6.
    View in: PubMed
  231. Walsh SV, Loda M, Torres CM, Antonioli D, Odze RD. P53 and beta catenin expression in chronic ulcerative colitis--associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. Am J Surg Pathol. 1999 Aug; 23(8):963-9.
    View in: PubMed
  232. Bao S, Chang MS, Auclair D, Sun Y, Wang Y, Wong WK, Zhang J, Liu Y, Qian X, Sutherland R, Magi-Galluzi C, Weisberg E, Cheng EY, Hao L, Sasaki H, Campbell MS, Kraeft SK, Loda M, Lo KM, Chen LB. HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. Cancer Res. 1999 May 1; 59(9):2023-8.
    View in: PubMed
  233. Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, Ho SM. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol. 1999 Mar; 154(3):863-70.
    View in: PubMed
  234. Sharifi S, Murphy M, Loda M, Pinkus GS, Khettry U. Nodular lymphoid lesion of the liver: an immune-mediated disorder mimicking low-grade malignant lymphoma. Am J Surg Pathol. 1999 Mar; 23(3):302-8.
    View in: PubMed
  235. Signoretti S, Murphy M, Cangi MG, Puddu P, Kadin ME, Loda M. Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. Am J Pathol. 1999 Jan; 154(1):67-75.
    View in: PubMed
  236. Magi-Galluzzi C, Murphy M, Cangi MG, Loda M. Proliferation, apoptosis and cell cycle regulation in prostatic carcinogenesis. Anal Quant Cytol Histol. 1998 Oct; 20(5):343-50.
    View in: PubMed
  237. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol. 1998 Sep; 153(3):681-7.
    View in: PubMed
  238. Jessup JM, Loda M. Prognostic markers in rectal carcinoma. Semin Surg Oncol. 1998 Sep; 15(2):131-40.
    View in: PubMed
  239. Yang M, Loda M, Sytkowski AJ. Identification of genes expressed differentially by LNCaP or PC-3 prostate cancer cell lines. Cancer Res. 1998 Aug 15; 58(16):3732-5.
    View in: PubMed
  240. Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch. 1998 May; 432(5):407-13.
    View in: PubMed
  241. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998 Apr 15; 58(8):1730-5.
    View in: PubMed
  242. Capodieci P, Magi-Galluzzi C, Moreira G, Zeheb R, Loda M. Automated in situ hybridization: diagnostic and research applications. Diagn Mol Pathol. 1998 Apr; 7(2):69-75.
    View in: PubMed
  243. Bao L, Loda M, Zetter BR. Thymosin beta15 expression in tumor cell lines with varying metastatic potential. Clin Exp Metastasis. 1998 Apr; 16(3):227-33.
    View in: PubMed
  244. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998 Mar; 159(3):941-5.
    View in: PubMed
  245. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1735-40.
    View in: PubMed
  246. Macri E, Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998-1999; 17(4):337-44.
    View in: PubMed
  247. Jessup JM, Loda M, Bleday R. Clinical and molecular prognostic factors in sphincter-preserving surgery for rectal cancer. Semin Radiat Oncol. 1998 Jan; 8(1):54-69.
    View in: PubMed
  248. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997 Aug 15; 57(16):3381-5.
    View in: PubMed
  249. Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, Loda M. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol. 1997 Aug; 10(8):839-45.
    View in: PubMed
  250. Ellis FH, Loda M. Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett's adenocarcinoma. Dis Esophagus. 1997 Jul; 10(3):165-71.
    View in: PubMed
  251. Selletti L, Taveggia G, Grioni G, Uggeri M, Loda M, Pastorelli GM. [Principles of a rehabilitation treatment for returning to work after a stabilization intervention with the Colorado method]. G Ital Med Lav Ergon. 1997 Jul-Sep; 19(3):76-9.
    View in: PubMed
  252. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 1997 Apr 1; 57(7):1259-63.
    View in: PubMed
  253. Lise M, Loda M, Fiorentino M, Mercurio AM, Summerhayes IC, Lavin PT, Jessup JM. Association between sucrase-isomaltase and p53 expression in colorectal cancer. Ann Surg Oncol. 1997 Mar; 4(2):176-83.
    View in: PubMed
  254. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997 Mar 1; 57(5):808-11.
    View in: PubMed
  255. Lee AK, Loda M, Mackarem G, Bosari S, DeLellis RA, Heatley GJ, Hughes K. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome. Cancer. 1997 Feb 15; 79(4):761-71.
    View in: PubMed
  256. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997 Feb; 3(2):231-4.
    View in: PubMed
  257. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ, Loda M. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest. 1997 Jan; 76(1):37-51.
    View in: PubMed
  258. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, Jessup JM, Loda M, Summerhayes IC. The DCC protein and prognosis in colorectal cancer. N Engl J Med. 1996 Dec 5; 335(23):1727-32.
    View in: PubMed
  259. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat Med. 1996 Dec; 2(12):1322-8.
    View in: PubMed
  260. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, Stork PJ. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol. 1996 Nov; 149(5):1553-64.
    View in: PubMed
  261. Leav I, Galluzzi CM, Ziar J, Stork PJ, Ho SM, Loda M. Mitogen-activated protein kinase and mitogen-activated kinase phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest. 1996 Sep; 75(3):361-70.
    View in: PubMed
  262. Loda M, Fiorentino M, Meckler J, Khettry U, Lewis D, Washburn K, Jenkins R, Mendoza AE, Samuelson J. Hepatitis C virus reinfection in orthotopic liver transplant patients with or without concomitant hepatitis B infection. Diagn Mol Pathol. 1996 Jun; 5(2):81-7.
    View in: PubMed
  263. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, Hughes KS. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996 Feb 1; 77(3):490-8.
    View in: PubMed
  264. DelSal G, Loda M, Pagano M. Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncog. 1996; 7(1-2):127-42.
    View in: PubMed
  265. Magi-Galluzzi C, Loda M. Molecular events in the early phases of prostate carcinogenesis. Eur Urol. 1996; 30(2):167-76.
    View in: PubMed
  266. Bosari S, Marchetti A, Buttitta F, Graziani D, Borsani G, Loda M, Bevilacqua G, Coggi G. Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol. 1995 Dec; 4(4):249-55.
    View in: PubMed
  267. Jessup JM, Lavin PT, Andrews CW, Loda M, Mercurio A, Minsky BD, Mies C, Cukor B, Bleday R, Steele G. Sucrase-isomaltase is an independent prognostic marker for colorectal carcinoma. Dis Colon Rectum. 1995 Dec; 38(12):1257-64.
    View in: PubMed
  268. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D. CDC25 phosphatases as potential human oncogenes. Science. 1995 Sep 15; 269(5230):1575-7.
    View in: PubMed
  269. Yao H, Labudda K, Rim C, Capodieci P, Loda M, Stork PJ. Cyclic adenosine monophosphate can convert epidermal growth factor into a differentiating factor in neuronal cells. J Biol Chem. 1995 Sep 1; 270(35):20748-53.
    View in: PubMed
  270. Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, Summerhayes IC. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene. 1995 Aug 17; 11(4):647-52.
    View in: PubMed
  271. Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res. 1995 Aug 15; 55(16):3509-12.
    View in: PubMed
  272. Gordon FD, Anastopoulos H, Khettry U, Loda M, Jenkins RL, Lewis WD, Trey C. Hepatitis C infection: a rare cause of fulminant hepatic failure. Am J Gastroenterol. 1995 Jan; 90(1):117-20.
    View in: PubMed
  273. Loda M, Lipman J, Cukor B, Bur M, Kwan P, DeLellis RA. Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity. Hum Pathol. 1994 Oct; 25(10):1050-6.
    View in: PubMed
  274. Florio T, Rim C, Hershberger RE, Loda M, Stork PJ. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Mol Endocrinol. 1994 Oct; 8(10):1289-97.
    View in: PubMed
  275. Loda M. Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. Hum Pathol. 1994 Jun; 25(6):564-71.
    View in: PubMed
  276. Fogt F, Vortmeyer AO, Ahn G, De Girolami U, Hunt RB, Daly T, Loda M. Neural cyst of the ovary with central nervous system microvasculature. Histopathology. 1994 May; 24(5):477-80.
    View in: PubMed
  277. Loda M, Fogt F, French FS, Posner M, Cukor B, Aretz HT, Alsaigh N. Androgen receptor immunohistochemistry on paraffin-embedded tissue. Mod Pathol. 1994 Apr; 7(3):388-91.
    View in: PubMed
  278. Fabbretti G, Valenti C, Loda M, Brisigotti M, Cozzutto C, Tonini GP, Callea F. N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol. 1993 Mar; 24(3):294-7.
    View in: PubMed
  279. Badiali M, Iolascon A, Loda M, Scheithauer BW, Basso G, Trentini GP, Giangaspero F. p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Diagn Mol Pathol. 1993 Mar; 2(1):23-8.
    View in: PubMed
  280. Giangaspero F, Rigobello L, Badiali M, Loda M, Andreini L, Basso G, Zorzi F, Montaldi A. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol. 1992 Jul; 16(7):687-93.
    View in: PubMed
  281. Lee AK, Wiley B, Dugan JM, Hamilton WH, Loda M, Heatley GJ, Cook L, Silverman ML. Quantitative DNA analysis and proliferation in breast carcinomas. A comparison between image analysis and flow cytometry. Pathol Res Pract. 1992 Jun; 188(4-5):428-32.
    View in: PubMed
  282. Loda M, Giangaspero F, Badiali M, Capodieci P, Pession A. p53 gene expression in medulloblastoma by quantitative polymerase chain reaction. Diagn Mol Pathol. 1992 Mar; 1(1):36-44.
    View in: PubMed
  283. Lee AK, Wiley B, Loda M, Bosari S, Dugan JM, Hamilton W, Heatley GJ, Cook L, Silverman ML. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol. 1992 Jan; 5(1):61-7.
    View in: PubMed
  284. Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K, Wolfe H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene. 1991 May; 6(5):857-62.
    View in: PubMed
  285. Loda M, Mendoza AE, O'Hara C, Crawford JM, Federman M, Goodman H. Well-differentiated hepatocellular carcinoma associated with long-term survival. Report of two cases. Virchows Arch A Pathol Anat Histopathol. 1991; 418(6):551-6.
    View in: PubMed
  286. Pearl RH, Clowes GH, Hirsch EF, Loda M, Grindlinger GA, Wolfort S. Prognosis and survival as determined by visceral amino acid clearance in severe trauma. J Trauma. 1985 Aug; 25(8):777-83.
    View in: PubMed
  287. Devereux DF, Redgrave TG, Loda MF, Clowes GH, Deckers PJ. Tumor-associated metabolism in the rat is a unique physiologic entity. J Surg Res. 1985 Feb; 38(2):149-53.
    View in: PubMed
  288. Clowes GH, McDermott WV, Williams LF, Loda M, Menzoian JO, Pearl R. Amino acid clearance and prognosis in surgical patients with cirrhosis. Surgery. 1984 Oct; 96(4):675-85.
    View in: PubMed
  289. Loda M, Clowes GH, Dinarello CA, George BC, Lane B, Richardson W. Induction of hepatic protein synthesis by a peptide in blood plasma of patients with sepsis and trauma. Surgery. 1984 Aug; 96(2):204-13.
    View in: PubMed
  290. Loda M, Clowes GH, Nespoli A, Bigatello L, Birkett DH, Menzoian JO. Encephalopathy, oxygen consumption, visceral amino acid clearance, and mortality in cirrhotic surgical patients. Am J Surg. 1984 Apr; 147(4):542-50.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Loda's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_